BEXIMCO PHARMA.GDR REGS 1 Cash Flow-to-Debt Ratio
BEXIMCO PHARMA.GDR REGS 1 cash flow-to-debt ratio. BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow-to-Debt Ratio of 0.48x as of June 2024, meaning its operating cash flow of €8.36 Billion could theoretically repay 0% of its total liabilities (€17.44 Billion) in one year. Check BEXIMCO PHARMA.GDR REGS 1 (R2WA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Cash flow-to-debt ratio of BEXIMCO PHARMA.GDR REGS 1 from 2022 to 2024. Historical debt coverage capacity for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. Check BEXIMCO PHARMA.GDR REGS 1 (R2WA) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BEXIMCO PHARMA.GDR REGS 1 Cash Flow-to-Debt Ratio by Year (2022–2024)
BEXIMCO PHARMA.GDR REGS 1 cash flow-to-debt ratio by year from 2022 to 2024. Year-by-year debt coverage analysis for BEXIMCO PHARMA.GDR REGS 1. For the full cash flow conversion analysis, see BEXIMCO PHARMA.GDR REGS 1 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.48x | €8.36 Billion | €17.44 Billion | ▲ +69.7% |
| 2023 | 0.28x | €6.08 Billion | €21.54 Billion | ▲ +16.6% |
| 2022 | 0.24x | €5.21 Billion | €21.51 Billion | — |